PANCREATIC CANCER NORTH AMERICA, INC.
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : a***n@p********************a.ca
Mission Statement
In the past 50 years, the survival rate for pancreatic cancer has only improved by 10%. This is not meaningful progress and patients cannot rely on hope alone to live through this deadly disease. PancONE Network Inc. (operating under the brand name Pancreatic Cancer North America) aims to disrupt the traditional approach to discovery in pancreatic cancer by bringing together multiple sectors, innovations, and novel methods to drive real change. Pancreatic Cancer North America is committed to working with all partners who believe as we do in coming together boldly to change the outcome for the world’s toughest cancer. We’ve raised enough sympathy. It’s time to raise survival rates.
About This Cause
Pancreatic Cancer North America (PCNA) is the evolution of 17 years of foundation-setting in Canada through Pancreatic Cancer Canada (PCC). As the only national organization committed to this deadly disease, PCC has been pivotal for Canadians affected by pancreatic cancer. While committing millions to research efforts, advocating for the voice of patients and their families, and educating the public and healthcare professionals on the stark realities of this cancer, PCC has formed allied partnerships with organizations in the United States and Europe. PCNA was established as a 501(c)3 with the mission of disrupting the decades-old approach to discovery by bringing together multiple sectors, innovations, and novel methods to drive real change. Over the first two years, PCNA's fundraising efforts have been focused on the generosity of individual donors. Their support enabled investment in a North American, multi-centered research initiative at major institutions across North America (Princess Margaret, Johns Hopkins, Dana-Farber, Memorial Sloan Kettering etc.) that created organoids from pancreatic cancer patients’ tumors in order to rapid test 100+ different drug therapies in real time, with the aim to determine what might work outside the standard of care portfolio. At the end of 2022, PCNA began the development of a strategic plan that focuses on diversification in revenue streams to include corporate partnerships, foundation funding and increased efforts in individual giving across digital platforms as well as direct, leadership-level giving. PCNA fundraising efforts will support large-scale investments in research to change the trajectory of this disease. We have seen the outcomes that investments in other cancer states have yielded, and are confident that the same results are possible for pancreatic cancer with the right level of investment in the right kinds of projects. PCNA is supporting research that will change survival rates for future generations. While we work to challenge the current status and invest in research that will change outcomes for pancreatic cancer patients, we are keenly aware that 90% of those diagnosed will die, often experiencing immense pain, suffering and distress. Palliative care is one of the most impactful forms of treatment and care we can give loved ones. It treats the “whole person” and is not focused on a cure, but rather relief and comfort. PCNA is committed to creating a national standard of excellence for palliative care that includes strategies and real measures to break down barriers to access and meets the needs of people living with serious illnesses like pancreatic cancer. PCNA is currently funding a cutting-edge study at Memorial Sloan Kettering (MSK – NYC) where researchers will test the results of mRNA vaccine treatment versus the standard of care in a group of pancreatic cancer patients. This study holds much promise and paves the way for an entirely new approach to treating the world’s toughest cancer. It will also provide a blueprint for mRNA vaccine development in other forms of cancer. PNCA is also investing in research at Dana-Farber Cancer Institute, looking at the effects of psilocybin on pain in advanced cancer patients. The study aims to assess the feasibility, safety, and efficacy of psilocybin as an intervention for pain in patients with advanced cancer, as an alterative to traditional opioids. Additional aims of the study are to alleviate the mental adjustment to a cancer diagnosis and psychological distress, while supporting spiritual well-being and health-related quality of life. PCNA is driving novel and innovative research forward by supporting bold, cutting-edge technology that holds real promise for patients of tomorrow, not only in pancreatic cancer, but across many forms of the disease. While pushing progress forward, those diagnosed today cannot be left behind. Supporting work to improve the palliative and end of life experience for pancreatic cancer patients is critical to PCNA's mission.